Dose-dependent lesions of the dopaminergic nigrostriatal pathway induced by instrastriatal injection of 6-hydroxydopamine

Animal models with partial lesions of the dopaminergic nigrostriatal pathway may be useful for developing neuroprotective and neurotrophic therapies for Parkinson's disease. To develop such a model, different doses of 6-hydroxydopamine (0.0, 0.625, 1.25, 2.5 and 5.0 micrograms/microliters in 3.5 microliters of saline) were unilaterally injected into the striatum of rats. Animals that received 1.25 to 5.0 micrograms/microliters 6-hydroxydopamine displayed dose-dependent amphetamine and apomorphine-induced circling. 6-Hydroxydopamine also caused dose-dependent reductions in [3H]mazindol-labeled dopamine uptake sites in the lesioned striatum and ipsilateral substantia nigra pars compacta (up to 93% versus contralateral binding), with smaller losses in the nucleus accumbens, olfactory tubercle and ventral tegmental area. In the substantia nigra pars compacta and the ventral tegmental area, the number of Nissl-stained neurons decreases in parallel with the reduction in [3H]mazindol binding. The reduction in [3H]mazindol binding in the striatum and the nucleus accumbens, and the reduction in [3H]mazindol binding and in the number of Nissl-stained neurons in the substantia nigra pars compacta and the ventral tegmental area is stable for up to 12 weeks after the lesion. Macroscopically, forebrain coronal sections showed normal morphology, except for rats receiving 5.0 micrograms/microliters 6-hydroxydopamine in which striatal cross-sectional area was reduced, suggesting that this high dose non-specifically damages intrinsic striatal neurons. Nissl-stained sections revealed an area of neuronal loss and intense gliosis centered around the needle track, which increased in size with the dose of neurotoxin. Striatal [3H]sulpiride binding was increased by 2.5 micrograms/microliters and 5.0 micrograms/microliters 6-hydroxydopamine, suggesting up-regulation of dopamine D2 receptors. Striatal binding of [3H]CGS 21680-labeled adenosine A2a receptors, but not of [3H]SCH 23390-labeled dopamine D1 receptors, was reduced at the highest dose, suggesting preservation of the striatal intrinsic neurons with the lower doses. This study indicates that intrastriatal injection of different doses of 6-hydroxydopamine can be used to cause increasing amounts of dopamine denervation, which could model Parkinson's disease of varying degrees of severity. Injecting 3.5 microliters of 2.5 micrograms/microliters 6-hydroxydopamine appears to be particularly useful as a general model of early Parkinson's disease, since it induces a lesion characterized by robust drug-induced rotation, changes in binding consistent with approximately 70% dopamine denervation, approximately 19% dopamine D22 receptor up-regulation, negligible intrinsic striatal damage and stability for at least 12 weeks. This study outlines a technique for inducing partial lesions of the nigrostriatal dopamine pathway in rats.(ABSTRACT TRUNCATED AT 400 WORDS)

[1]  H. Robertson,et al.  Dopamine receptor interactions: some implications for the treatment of Parkinson's disease , 1992, Trends in Neurosciences.

[2]  S. Snyder,et al.  Differential visualization of dopamine and norepinephrine uptake sites in rat brain using [3H]mazindol autoradiography , 1985, The Journal of neuroscience : the official journal of the Society for Neuroscience.

[3]  Greg A. Gerhardt,et al.  Correlation of apomorphine- and amphetamine-induced turning with nigrostriatal dopamine content in unilateral 6-hydroxydopamine lesioned rats , 1993, Brain Research.

[4]  B. Rosen,et al.  1‐Methyl‐4‐Phenylpyridinium Produces Excitotoxic Lesions in Rat Striatum as a Result of Impairment of Oxidative Metabolism , 1992, Journal of neurochemistry.

[5]  M. Kilbourn,et al.  Repeated reserpine administration reduces in vivo [18F]GBR 13119 binding to the dopamine uptake site. , 1992, European journal of pharmacology.

[6]  C. Marsden,et al.  New insights into the cause of Parkinson's disease , 1992, Neurology.

[7]  C. Pycock.  Turning behaviour in animals , 1980, Neuroscience.

[8]  A. Herbet,et al.  Specificity of dopaminergic neuronal degeneration induced by intracerebral injection of 6-hydroxydopamine in the nigrostriatal dopamine system , 1976, Brain Research.

[9]  M. Verrier,et al.  MPTP produces reversible disappearance of tyrosine hydroxylase-containing retinal amacrine cells , 1990, Brain Research.

[10]  R. H. Stellwagen,et al.  Slow changes of tyrosine hydroxylase gene expression in dopaminergic brain neurons after neurotoxin lesioning: a model for neuron aging. , 1992, Brain research. Molecular brain research.

[11]  Y. Agid,et al.  Tyrosine hydroxylase protein and messenger RNA in the dopaminergic nigral neurons of patients with Parkinson's disease , 1993, Brain Research.

[12]  C. Gerfen.  The neostriatal mosaic: multiple levels of compartmental organization in the basal ganglia. , 1992, Annual review of neuroscience.

[13]  J. Cadet,et al.  Effect of Unilateral Perinatal Hypoxic‐Ischemic Brain Injury in the Rat on Dopamine D1 and D2 Receptors and Uptake Sites: A Quantitative Autoradiographic Study , 1991, Journal of neurochemistry.

[14]  K. S. Bankiewicz,et al.  A 6-hydroxydopamine-induced selective parkinsonian rat model , 1989, Brain Research.

[15]  W. Tatton,et al.  Dose-dependent destruction of the coeruleus-cortical and nigral-striatal projections by MPTP , 1990, Brain Research.

[16]  E. Hirsch,et al.  Decreased tyrosine hydroxylase messenger RNA in the surviving dopamine neurons of the substantia nigra in parkinson's disease: An in situ hybridization study , 1990, Neuroscience.

[17]  A. D. Smith,et al.  The neural network of the basal ganglia as revealed by the study of synaptic connections of identified neurones , 1990, Trends in Neurosciences.

[18]  T. Joh,et al.  Transneuronal regulation of tyrosine hydroxylase expression in olfactory bulb of mouse and rat , 1983, The Journal of neuroscience : the official journal of the Society for Neuroscience.

[19]  B. Hyman,et al.  Age‐Dependent Striatal Excitotoxic Lesions Produced by the Endogenous Mitochondrial Inhibitor Malonate , 1993, Journal of neurochemistry.

[20]  Anders Björklund.  Neural transplantation — an experimental tool with clinical possibilities , 1991, Trends in Neurosciences.

[21]  E. Richfield,et al.  Quantitative autoradiography of [3H]sulpiride binding sites in rat brain , 1984, Neuroscience Letters.

[22]  G. Wooten,et al.  Differential localization of A2a adenosine receptor mRNA with D1 and D2 dopamine receptor mRNA in striatal output pathways following a selective lesion of striatonigral neurons , 1993, Brain Research.

[23]  Marian DiFiglia,et al.  Excitotoxic injury of the neostriatum: a model for Huntington's disease , 1990, Trends in Neurosciences.

[24]  M. Dubocovich,et al.  Binding characteristics of the dopamine uptake inhibitor [3H]nomifensine to striatal membranes. , 1985, Biochemical pharmacology.

[25]  M. Abercrombie.  Estimation of nuclear population from microtome sections , 1946, The Anatomical record.

[26]  R. Burke,et al.  Naturally Occurring Cell Death during Postnatal Development of the Substantia Nigra Pars Compacta of Rat , 1993, Molecular and Cellular Neuroscience.

[27]  U. Ungerstedt,et al.  Quantitative recording of rotational behavior in rats after 6-hydroxy-dopamine lesions of the nigrostriatal dopamine system. , 1970, Brain research.

[28]  R. Porter,et al.  Inhibition of Succinate Dehydrogenase by Malonic Acid Produces an “Excitotoxic” Lesion in Rat Striatum , 1993, Journal of neurochemistry.

[29]  R. Wurtman,et al.  Partial lesions of the dopaminergic nigrostriatal system in rat brain: biochemical characterization , 1980, Brain Research.

[30]  G. Paxinos,et al.  The Rat Brain in Stereotaxic Coordinates , 1983 .

[31]  C. Finch,et al.  Chronic lesions differentially decrease tyrosine hydroxylase messenger RNA in dopaminergic neurons of the substantia nigra. , 1989, Brain research. Molecular brain research.

[32]  J. Obeso,et al.  Decreased tyrosine hydroxylase content in the dopaminergic neurons of MPTP–intoxicated monkeys: Effect of levodopa and GM1 ganglioside therapy , 1994, Annals of neurology.

[33]  U. Muthane,et al.  Differences in Nigral Neuron Number and Sensitivity to 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine in C57/bl and CD-1 Mice , 1994, Experimental Neurology.

[34]  R. Beninger,et al.  On the interpretation of asymmetries of posture and locomotion produced with dopamine agonists in animals with unilateral depletion of striatal dopamine , 1991, Progress in Neurobiology.

[35]  R. Baldessarini,et al.  Lack of increase in dopamine transporter binding or function in rat brain tissue after treatment with blockers of neuronal uptake of dopamine , 1991, Neuropharmacology.

[36]  W. Weiner,et al.  1-Methyl-4-phenylpyridinium (MPP+) but not 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) selectively destroys dopaminergic neurons in cultures of dissociated rat mesencephalic neurons , 1986, Neuroscience Letters.

[37]  E. Eidelberg,et al.  Injury of Catecholaminergic Neurons after Acute Exposure to MPTP , 1987 .

[38]  W. Turski,et al.  Aminooxyacetic acid produces excitotoxic lesions in the rat striatum , 1991, Synapse.

[39]  D. Gash,et al.  Effect of bilateral 6-OHDA lesions of the substantia nigra on locomotor activity in the rat , 1994, Brain Research.

[40]  M. Sofroniew,et al.  Loss of transmitter-associated enzyme staining following axotomy does not indicate death of brainstem cholinergic neurons , 1988, Brain Research.

[41]  R. Wise,et al.  Retrograde fluorescent tracing of substantia nigra neurons combined with catecholamine histofluorescence , 1980, Brain Research.

[42]  U. Ungerstedt.  Striatal dopamine release after amphetamine or nerve degeneration revealed by rotational behaviour. , 1971, Acta physiologica Scandinavica. Supplementum.

[43]  Stephen J. Fink,et al.  Colocalization of D1 and D2 dopamine receptor mRNAs in striatal neurons , 1993, Brain Research.

[44]  T. H. Burnstine,et al.  Movement Disorders 2 , 1988, Neurology.

[45]  B. Parsons,et al.  Adenosine receptor antagonists potentiate dopamine receptor agonist-induced rotational behavior in 6-hydroxydopamine-lesioned rats , 1993, Brain Research.

[46]  J. Cadet,et al.  Long-term behavioral and biochemical effects of 6-hydroxydopamine injections in rat caudate-putamen , 1991, Brain Research Bulletin.

[47]  J. Palacios,et al.  Adenosine A2 receptors: Selective localization in the human basal ganglia and alterations with disease , 1991, Neuroscience.

[48]  Fred H. Gage,et al.  Partial lesion of the substantia nigra: relation between extent of lesion and rotational behavior , 1991, Brain Research.

[49]  R. Albin,et al.  Alternative excitotoxic hypotheses , 1992, Neurology.

[50]  M. Törnwall,et al.  Effects of three types of catechol O-methylation inhibitors on L-3,4-dihydroxyphenylalanine-induced circling behaviour in rats. , 1993, European journal of pharmacology.

[51]  M. Beal,et al.  Does impairment of energy metabolism result in excitotoxic neuronal death in neurodegenerative illnesses? , 1992, Annals of neurology.

[52]  W. Tatton,et al.  Transmitter synthesis increases in substantia nigra neurons of the aged mouse , 1991, Neuroscience Letters.

[53]  T. Ho¨kfelt,et al.  Retrograde peroxidase tracing of neurons combined with transmitter histochemistry , 1975, Brain Research.

[54]  J. Cedarbaum,et al.  The Therapeutic Potential of Neurotrophic Factors in the Treatment of Parkinson's Disease , 1993, Experimental Neurology.

[55]  Charles Watson,et al.  Bregma, lambda and the interaural midpoint in stereotaxic surgery with rats of different sex, strain and weight , 1985, Journal of Neuroscience Methods.

[56]  Y. Agid,et al.  Immunocytochemical Quantification of Tyrosine Hydroxylase at a Cellular Level in the Mesencephalon of Control Subjects and Patients with Parkinson's and Alzheimer's Disease , 1993, Journal of neurochemistry.

[57]  R. Burke,et al.  Effect of striatal lesion with quinolinate on the development of substantia nigra dopaminergic neurons: a quantitative morphological analysis. , 1992, Developmental neuroscience.

[58]  J. Sladek,et al.  Dopamine cell replacement: Parkinson's disease. , 1990, Annual review of neuroscience.

[59]  J. Cadet,et al.  Retrograde degeneration of nigrostriatal neurons induced by intrastriatal 6-hydroxydopamine injection in rats , 1991, Brain Research Bulletin.

[60]  D. Reis,et al.  Reversible changes in the activities and amounts of tyrosine hydroxylase in dopamine neurons of the substantia nigra in response to axonal injury as studied by immunochemical and immunocytochemical methods , 1978, Brain Research.

[61]  P. Seeman,et al.  The Dopamine Transporter Is Absent in Parkinsonian Putamen and Reduced in the Caudate Nucleus , 1991, Journal of neurochemistry.

[62]  U. McCann,et al.  Neurotoxic Amphetamine Analogues: Effects in Monkeys and Implications for Humans a , 1992, Annals of the New York Academy of Sciences.

[63]  M. Kuhar,et al.  Quantitative receptor mapping by autoradiography: some current technical problems , 1985, Trends in Neurosciences.

[64]  W. H. Oertel,et al.  Progressive degeneration of nigrostriatal dopamine neurons following intrastriatal terminal lesions with 6-hydroxydopamine: A combined retrograde tracing and immunocytochemical study in the rat , 1994, Neuroscience.

[65]  M. Williams,et al.  Direct autoradiographic localization of adenosine A2 receptors in the rat brain using the A2-selective agonist, [3H]CGS 21680. , 1989, European journal of pharmacology.

[66]  T. Hattori,et al.  Is there a non-dopaminergic nigrostriatal pathway? , 1981, Neuroscience.

[67]  T. Stone.  Handbook of chemical neuroanatomy vol. 1: Methods in chemical neuroanatomy: edited by A. Björklund and T. Hökfelt, Elsevier Science Publishers, 1983. Dfl 330.00/US$140.50 (xxvi + 548 pages) ISBN 0 444 90281 3 , 1984 .

[68]  R. Burke,et al.  Neonatal hypoxic-ischemic or excitotoxic striatal injury results in a decreased adult number of substantia nigra neurons , 1992, Neuroscience.

[69]  H. Teräväinen,et al.  Animal models of parkinsonism. , 1990, Pharmacology & toxicology.

[70]  U. Ungerstedt,et al.  Supersensitivity to apomorphine following destruction of the ascending dopamine neurons: quantification using the rotational model. , 1977, European journal of pharmacology.

[71]  S. Snyder,et al.  Dopamine receptor binding enhancement accompanies lesion-induced behavioral supersensitivity. , 1977, Science.

[72]  B. Hyman,et al.  Aminooxyacetic Acid Results in Excitotoxin Lesions by a Novel Indirect Mechanism , 1991, Journal of neurochemistry.

[73]  W. Weiner,et al.  Selective Destruction of Cultured Dopaminergic Neurons from Fetal Rat Mesencephalon by 1‐Methyl‐4‐Phenylpyridinium: Cytochemical and Morphological Evidence , 1988, Journal of neurochemistry.

[74]  C. D. Stern,et al.  Handbook of Chemical Neuroanatomy Methods in Chemical Neuroanatomy. Edited by A. Bjorklund and T. Hokfelt. Elsevier, Amsterdam, 1983. Cloth bound, 548 pp. UK £140. (Volume 1 in the series). , 1986, Neurochemistry International.

[75]  J. Cadet,et al.  Sham transplantation protects against 6-hydroxydopamine-induced dopaminergic toxicity in rats: behavioral and morphological evidence , 1991, Brain Research.